Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | RBP4 | P02753 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
| ▸ | GABRE | P78334 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407862 | 0.82 | HRH4 (0.59) | HRH4DAOATAD2CNR2RBP4 | |
| SCHEMBL30052471 | 0.82 | HRH4 (0.59) | HRH4DAOATAD2CNR2RBP4 | |
| SCHEMBL1203267 | 0.80 | HRH4 (0.57) | HRH4DAOATAD2CNR2RBP4 | |
| Hydrochloric Acid SCHEMBL28102419 | 0.80 | HRH4 (0.57) | HRH4DAOATAD2CNR2RBP4 | |
| SCHEMBL29414319 | 0.80 | HRH4 (0.57) | HRH4DAOATAD2CNR2RBP4 | |
| SCHEMBL1194081 | 0.79 | HRH4 (0.56) | HRH4DAOATAD2CNR2RBP4 | |
| SCHEMBL29362530 | 0.79 | HRH4 (0.56) | HRH4DAOATAD2CNR2RBP4 | |
| SCHEMBL4034426 | 0.78 | HRH4 (0.56) | HRH4DAOATAD2CNR2RBP4 | |
| SCHEMBL30147746 | 0.78 | CNR2 (0.59) | HRH4DAOATAD2CNR2RBP4 | |
| SCHEMBL1439839 | 0.78 | CNR2 (0.59) | HRH4DAOATAD2CNR2RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181252-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181252-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9139587-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-8993586-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993586-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859773-B2 | N1/N2-lactam acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140288111-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8802690-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130296319-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-8507681-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507681-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130030181-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025098-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | HRH4 2260/4885DAO 1319/4885ATAD2 1705/4885 |
| US-20150152109-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | HRH4 2260/4885DAO 1319/4885ATAD2 1705/4885 |
| US-20140288111-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, PC, ACACB | HRH4 2219/4885DAO 1825/4885ATAD2 1603/4885 |
| US-20130296319-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, PC, ACACB | HRH4 2167/4885DAO 1816/4885ATAD2 1563/4885 |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | HRH4 2260/4885DAO 1319/4885ATAD2 1705/4885 |
| US-20130030181-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | HRH4 2219/4885DAO 1825/4885ATAD2 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.